Itorihenz 150 Capsule SR contains Itopride 150 mg, a prokinetic agent used primarily to enhance gastrointestinal motility. Itopride acts by inhibiting dopamine D2 receptors and antagonizing acetylcholinesterase activity, thereby increasing acetylcholine levels in the gastrointestinal tract, which facilitates gastric emptying and improves motility. This medication is indicated for the treatment of functional dyspepsia, gastroesophageal reflux disease (GERD), and other conditions associated with delayed gastric emptying or impaired gastrointestinal motility. Itorihenz 150 Capsule SR is formulated as a sustained-release preparation to ensure prolonged therapeutic effects and improved patient compliance. The drug is generally well tolerated; however, common adverse effects may include mild gastrointestinal disturbances such as diarrhea, abdominal pain, or nausea. Caution is advised in patients with hypersensitivity to Itopride or any of the capsule excipients. It is contraindicated in individuals with mechanical obstruction of the gastrointestinal tract or known pheochromocytoma. Dosage should be individualized based on clinical response and tolerability, and it is recommended to be taken as prescribed by a healthcare professional. Regular monitoring may be necessary in long-term use to assess efficacy and detect any potential adverse reactions. Itorihenz 150 Capsule SR should be stored in a cool, dry place away from direct sunlight.